SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the U.S. Food and Drug Administration (FDA) in partnership with the Reagan-Udall Foundation for the FDA. The in-person and virtual event, titled "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest," will explore the landscape for ketamine usage and increasing public interest in ketamine as a treatment for conditions such as depression and chronic pain.
CEO Eric Weisblum and a scientific advisor to Silo will attend the scheduled discussions and engage with speakers and attendees including clinicians, academic researchers, patients and patient advocates, professional organizations, and federal partners.
Silo Pharma's novel drug candidates utilize ketamine as a primary therapeutic agent:
- Silo's lead program, SPC-15, is formulated and delivered as an intranasal prophylactic treatment for PTSD and stress-induced anxiety disorder—underserved markets with few approved drugs. ...